Work

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9512

Authors: Yousef Zakharia, Olivier Rixe, John Harris Ward, Joseph J. Drabick, Montaser F. Shaheen, Mohammed M. Milhem, David Munn, Eugene Paul Kennedy, Nicholas N. Vahanian, Charles J. Link, Robert R. McWilliams

Institutions: University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, Augusta University, University of Utah, Huntsman Cancer Institute, Penn State Milton S. Hershey Medical Center, UNM Comprehensive Cancer Center, NewLink Genetics (United States), Mayo Clinic

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890041342

Cites:

Cited by: 41

Related to: 10